PharmaPoint: Healthcare-Associated Gram-Negative Infections - Global Drug Forecast and Market Analysis to 2026

  • ID: 4421318
  • Report
  • Region: Global
  • 379 pages
  • GlobalData
1 of 4

FEATURED COMPANIES

  • Achaogen
  • Allergan
  • MedImmune LLC
  • Pfizer
  • Shionogi & Co., Ltd.
  • Wockhardt Ltd.
  • MORE
PharmaPoint: Healthcare-Associated Gram-Negative Infections - Global Drug Forecast and Market Analysis to 2026

Summary

Bacterial infections represent a frequent occurrence in humans. Fortunately, a majority of these infections are successfully eliminated by the native and adaptive immune system. The majority of remaining infections that do require medical assistance can be addressed by physicians outside the hospital setting using a set of generic antibiotics commonly prescribed throughout the seven major markets (7MM; US, France, Germany, Italy, Spain, UK, and Japan).

Global marketplace for healthcare-associated infections (HAIs) caused by Gram-negative bacteria-which, for the purpose of this report, consist of the catheter-associated urinary tract infections (CAUTI), central-line-associated bloodstream infections (CLABSI), hospital-associated pneumonia (HAP), ventilator-associated pneumonia (VAP), and surgical site infections (SSI) leading to intra-abdominal infections (IAI), and are caused by either Acinetobacter baumannii, Enterobacter spp, Escherichia coli, Klebsiella spp, or Pseudomonas aeruginosa was worth approximately US$1.3B in 2016.

It is expected that the market will exceed $3.6B in sales by 2026, at a Compound Annual Growth Rate (CAGR) of 10.6% from 2016-2026. These sales are projected to originate predominantly from the US, followed by Germany and France. This growth will be dominated by the launch of multiple pipeline products, which will contribute a combined 73% of the sales in 2026.

The current antibiotic pipeline is dominated by derivatives of commonly used scaffolds and combinations of beta-lactam antibiotics with beta-lactamases. However, the early stage pipeline includes novel approaches for new scaffolds and alternative approaches to combat resistance in Gram-negative bacteria, although most are currently in pre-clinical development.

The report "PharmaPoint: Healthcare-Associated Gram-Negative Infections - Global Drug Forecast and Market Analysis to 2026", provides the overview of HAIs caused by Gram-negative bacteria, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and current management strategies.

Particularly, this report provides the following:
  • Topline market revenue from 2016-2026 for HAIs caused by Gram-negative bacteria. Annual cost of therapy (ACOT) and major pipeline product sales in this forecast period are included.
  • Key topics covered include current treatment options, unmet needs and opportunities, and the drivers and barriers affecting therapeutics sales in the 7MM.
  • Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and detailed analysis of late-stage pipeline products.
  • Analysis of the current and future market competition in the global therapeutics market for HAIs caused by Gram-negative bacteria. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Companies mentioned in this report: Merck & Co, Pfizer, The Medicines Company, Shionogi & Co Ltd, Tetraphase Pharmaceuticals Inc, MerLion Pharmaceuticals Pte Ltd, Achaogen, Aridis Pharmaceuticals, MedImmune LLC, Allergan.

Scope:
  • Overview of HAIs caused by Gram-negative bacteria, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and current management strategies.
  • Topline market revenue from 2016-2026 for HAIs caused by Gram-negative bacteria. Annual cost of therapy (ACOT) and major pipeline product sales in this forecast period are included.
  • Key topics covered include current treatment options, unmet needs and opportunities, and the drivers and barriers affecting therapeutics sales in the 7MM.
  • Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and detailed analysis of late-stage pipeline products.
  • Analysis of the current and future market competition in the global therapeutics market for HAIs caused by Gram-negative bacteria. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Reasons to buy:

The report will enable you to:
  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the global therapeutics market for HAIs caused by Gram-negative bacteria.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the therapeutics market for HAIs caused by Gram-negative bacteria in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Achaogen
  • Allergan
  • MedImmune LLC
  • Pfizer
  • Shionogi & Co., Ltd.
  • Wockhardt Ltd.
  • MORE
1. List of Tables and Figures

2 Executive Summary
2.1 Launch of Patented Antibiotics Will Drive Solid Growth Over the Forecast Period
2.2 Pipeline Portfolios Target Highly Resistant Bacteria in Strong Collaborations With Governments
2.3 Drug Portfolios Address Some Unmet Needs, but Some Opportunities Remain With New Foreseeable Challenges
2.4 Companies Must Quickly Adapt to Exploit Opportunities in an Evolving Marketplace
2.5 Novel Antibiotics Are Poised to Drive Growth Despite Entering a Highly Genericized Marketplace
2.6 What Do Physicians Think?

3 Introduction
3.1 Catalyst
3.2 Related Reports
3.3 Upcoming Related Reports

4 Disease Overview
4.1 Infection Scope and Coverage Overview
4.2 Etiology and Pathophysiology
4.2.1 Etiology
4.2.2 Pathophysiology
4.3 Symptoms
4.4 Prognosis

5 Epidemiology
5.1 Disease Background
5.2 Risk Factors and Comorbidities
5.3 Global and Historical Trends
5.3.1 US
5.3.2 5EU
5.3.3 Japan
5.4 Forecast Methodology
5.4.1 Sources
5.4.2 Forecast Assumptions and Methods
5.5 Epidemiological Forecast for Suspected HAIs and Gram-Negative HAIs (2016-2026)
5.5.1 Suspected Incident Cases of Select HAIs
5.5.2 Diagnosed Incident Cases of Select Gram-Negative HAIs
5.5.3 Suspected Incident Cases of Select HAIs by Infection Site
5.5.4 Diagnosed Incident Cases of Select Gram-Negative HAIs by Infection Site
5.5.5 Diagnosed Incident Cases of Select Gram-Negative HAIs by Causative Agent
5.6 Discussion
5.6.1 Epidemiological Forecast Insight
5.6.2 Limitations of the Analysis
5.6.3 Strengths of the Analysis

6 Disease Management
6.1 Diagnosis and Treatment Overview
6.1.1 Diagnosis
6.1.2 Treatment Guidelines
6.1.3 Clinical Practice
6.1.4 Antibiotic Stewardship Programs
6.1.5 Off-Label Use of Antibiotics
6.2 US

….
6.3 5EU

.
6.4 Japan….

7 Competitive Assessment
7.1 Overview
7.2 Product Profiles - Beta-Lactam Antibiotics
7.2.1 Overview
7.2.2 Fixed Dose Beta-Lactam Combination Drugs
7.2.3 Monobactam antibiotics
7.2.4 Carbapenems
7.2.5 Cephalosporins
7.3 Product Profiles - Fluoroquinolones
7.3.1 Overview
7.3.2 Levofloxacin (numerous brand names)
7.3.3 Ciprofloxacin (numerous brand names)
7.3.4 Moxifloxacin (numerous brand names)
7.4 Product Profiles - Polymixins
7.4.1 Overview
7.4.2 Forecast
7.5 Product Profiles - Aminoglycosides
7.5.1 Overview
7.5.2 Amikacin (numerous brand names)
7.5.3 Gentamicin (numerous brand names)
7.5.4 Tobramycin (numerous brand names)
7.6 Product Profiles - Tetracyclines
7.6.1 Tygacil (tigecycline)
7.7 Product Profiles - Other Antibiotics

8 Unmet Needs Assessment and Opportunity Analysis
8.1 Overview
8.2 Novel Approaches in Drug Development to Address Antibiotic Resistance
8.2.1 Unmet Need
8.2.2 Gap Analysis
8.2.3 Opportunity
8.3 Novel Broad-Spectrum Antibiotics
8.3.1 Unmet Need
8.3.2 Gap Analysis
8.3.3 Opportunity
8.4 Antibiotics Positioned as Pathogen- and Resistance-Specific Therapies
8.4.1 Unmet Need
8.4.2 Gap Analysis
8.4.3 Opportunity
8.5 Expansion of Antimicrobial Stewardship Programs and Awareness
8.5.1 Unmet Need
8.5.2 Gap Analysis
8.5.3 Opportunity
8.6 Financial Incentives for Drug Development and Collaborative Efforts Between Governments/Non-Profits/For-Profits
8.6.1 Unmet Need
8.6.2 Gap Analysis
8.6.3 Opportunity
8.7 Improved Diagnostics for Pathogens and Resistance Patterns
8.7.1 Unmet Need
8.7.2 Gap Analysis
8.7.3 Opportunity
8.8 Improving the Safety and Administration Profile of Antibiotics
8.8.1 Unmet Need
8.8.2 Gap Analysis
8.8.3 Opportunity
8.9 Improved Clinical Trial Design
8.9.1 Unmet Need
8.9.2 Gap Analysis
8.9.3 Opportunity
8.10 Improved Prevention of Healthcare-Associated Infections
8.10.1 Unmet Need
8.10.2 Gap Analysis
8.10.3 Opportunity

9 Pipeline Assessment
9.1 Overview
9.2 Promising Drugs in Clinical Development
9.2.1 Antibiotics
9.2.2 Antibodies
9.3 Other Drugs in Development

10 Current and Future Players
10.1 Overview
10.2 Trends in Corporate Strategy
10.3 Company Profiles - Current Players
10.3.1 Pfizer
10.3.2 Merck& Co.
10.3.3 The Medicines Company
10.3.4 Shionogi & Co., Ltd.
10.3.5 Tetraphase Pharmaceuticals Inc.
10.3.6 MerLion Pharmaceuticals Pte., Ltd.
10.3.7 Achaogen
10.3.8 Aridis Pharmaceuticals
10.3.9 MedImmune LLC
10.3.10 Allergan
10.4 Other Companies With Early-Stage Products
10.4.1 Roche/Genentech
10.4.2 Wockhardt Ltd.
10.4.3 Allecra
10.4.4 Zavante

11 Market Outlook
11.1 Global Markets
11.1.1 Forecast
11.1.2 Drivers and Barriers - Global Issues
11.2 US

…..
11.2.1 Forecast
11.2.2 Key Events
11.2.3 Drivers and Barriers
11.3 5EU

.
11.3.1 Forecast
11.3.2 Key Events
11.3.3 Drivers and Barriers
11.4 Japan
11.4.1 Forecast
11.4.2 Key Events
11.4.3 Drivers and Barriers

12 Appendix
12.1 Bibliography
12.2 Abbreviations
12.3 Methodology
12.3.1 Forecasting Methodology
12.3.2 Suspected Infections and Diagnosed Patients
12.3.3 Percent Drug-Treated Patients
12.3.4 Antibiotic Resistance Patterns
12.3.5 Drugs Included in Each Therapeutic Class
12.3.6 Launch and Patent Expiry Dates
12.3.7 General Pricing Assumptions
12.3.8 Individual Drug Assumptions
12.3.9 Generic Erosion
12.3.10 Pricing of Pipeline Agents
12.4 Primary Research - Key Opinion Leaders Interviewed for This Report
12.5 Primary Research - Prescriber Survey
12.6 About the Authors
12.6.1 Analyst
12.6.2 Therapy Area Director
12.6.3 Epidemiologist
12.6.4 Reviewers
12.6.5 Global Director of Therapy Analysis and Epidemiology
12.6.6 Global Head and EVP of Healthcare Operations and Strategy
12.7 About
12.8 Contact Us
12.9 Disclaimer

List of Tables
Table 1: Healthcare-Associated Infections by Gram-Negative Bacteria: Key Metrics in the Seven Major Pharmaceutical Markets
Table 2: Characteristics of Most Important Gram-Negative Bacteria
Table 3: Prevalence of Antibiotic Resistance in Gram-Negative Bacteria Throughout the 7MM
Table 4: Symptoms of HAIs Caused by Gram-Negative Bacteria
Table 5: Risk Factors for Diagnosed Incident Cases of HAIs
Table 6: 7MM, Suspected Incident Cases of Select HAIs, Ages =18 Years, Both Sexes, N, Select Years 2016-2026
Table 7: 7MM, Diagnosed Incident Cases of Select Gram-Negative HAIs, Ages =18 Years, Both Sexes, N, Select Years 2016-2026
Table 8: National and International Treatment Guidelines for HAIs
Table 9: HAI Disease Management, Country Profile - US
Table 10: HAI Disease Management, Region Profile - 5EU
Table 11: HAI Disease Management, Region Profile - Japan
Table 12: Common Susceptibility Patterns in Gram-Negative Bacteria Isolated From the General Hospital Setting (non-ICU) and ICUs
Table 13: Leading Branded Treatments for HAI, 2016
Table 14: SWOT Analysis of Main Antibiotic Classes for HAIs Caused by Gram-Negative Bacteria
Table 15: Product Profile - Avycaz
Table 16: Efficacy of Avycaz in Patients with cIAIs
Table 17: Efficacy of Avycaz in Patients with cUTIs
Table 18: Safety of Avycaz
Table 19: Product Profile - Zerbaxa
Table 20: Efficacy of Zerbaxa in Patients with cIAIs
Table 21: Efficacy of Zerbaxa in Patients with cUTIs
Table 22: Safety of Zerbaxa
Table 23: Product Profile - Piperacillin/tazobactam
Table 24: Efficacy of Piperacillin/tazobactam in Patients with cIAIs
Table 25: Efficacy of Piperacillin/tazobactam in Patients with HAP
Table 26: Efficacy of Piperacillin/tazobactam in Patients with cUTIs
Table 27: Safety of Piperacillin/Tazobactam
Table 28: Product Profile - Ticarcillin/clavulanate
Table 29: Efficacy of Ticarcillin/clavulanate in Patients with cIAIs1
Table 30: Product Profile - Aztreonam
Table 31: Efficacy of Aztreonam
Table 32: Safety of Aztreonam in Patients with Bacterial Infections
Table 33: Product Profile - Doribax
Table 34: Efficacy of Doribax in Patients with cIAIs
Table 35: Efficacy of Doribax in Patients with cUTIs
Table 36: Safety of Doribax
Table 37: Product Profile - Invanz
Table 38: Efficacy of Invanz in Patients with cIAIs
Table 39: Efficacy of Invanz in Patients with cUTIs
Table 40: Safety of Invanz
Table 41: Most Frequently Used Cephalosporins in HAIs
Table 42: Product Profile - Levofloxacin
Table 43: Efficacy of Levaquin in Patients with Nosocomial Pneumonia
Table 44: Efficacy of Levaquin in Patients with cUTIs and Acute Pyelonephritis
Table 45: Safety of Levofloxacin in Patients with Bacterial Infections
Table 46: Product Profile - Ciprofloxacin
Table 47: Efficacy of Ciprofloxacin in Patients with cUTIs
Table 48: Safety of Ciprofloxacin in Patients with Bacterial Infections
Table 49: Product Profile - Moxifloxacin
Table 50: Efficacy of Moxifloxacin in Patients with cIAIs
Table 51: Safety of Moxifloxacin in Patients with Bacterial Infections
Table 52: Aminoglycoside Susceptibility of Strains Isolated from Hospitalized Patients with Pneumonia*
Table 53: Product Profile - Amikacin
Table 54: Efficacy of Amikacin in Patients with Bacterial Infections
Table 55: Safety of Amikacin in Patients with Bacterial Infections
Table 56: Product Profile - Gentamicin
Table 57: Efficacy of Gentamicin in Patients with Bacterial Infections
Table 58: Safety of Gentamicin in Patients with Bacterial Infections
Table 59: Product Profile - Tobramycin
Table 60: Product Profile - Tygacil
Table 61: Efficacy of Tygacil in Patients with cIAIs
Table 62: Efficacy of Tygacil in Patients with HAP/VAP
Table 63: Safety of Tygacil
Table64: Infrequently Used Antibiotics for the Treatment of HAI Caused by Gram-Negative Bacteria
Table 65: Key Late-Stage Pipeline Agents for HAIs Caused by Gram-Negative Bacteria, 2017
Table 66: Product Profile - Avibactam/Aztreonam
Table 67: Pathogen Susceptibility to Avibactam/Aztreonam
Table 68: Avibactam/Aztreonam SWOT Analysis, 2017
Table 69: Product Profile - Meropenem/Vaborbactam
Table 70: Meropenem/Vaborbactam - Phase III Clinical Trials
Table 71: Meropenem/Vaborbactam SWOT Analysis, 2017
Table 72: Product Profile - Relebactam/Imipenem/Cilastin
Table 73: Relebactam/Imipenem/Cilastin - Phase II and Phase III Clinical Trials
Table 74: Relebactam/Imipenem/Cilastin - Phase II Results (cIAI/cUTI)
Table 75: Safety of Relebactam/Imipenem/Cilastin
Table 76: Relebactam/Imipenem/Cilastin SWOT Analysis, 2017
Table 77: Product Profile - Cefiderocol
Table 78: Cefiderocol - Phase II and Phase III Clinical Trials
Table 79: Cefiderocol SWOT Analysis, 2017
Table 80: Product Profile - Eravacycline
Table 81: Eravacycline - Phase II and Phase III Clinical Trials
Table 82: Eravacycline - Phase III Clinical Trials Results for cIAIs
Table 83: Eravacycline - Safety Profile
Table 84: Eravacycline SWOT Analysis, 2017
Table 85: Product Profile - Finafloxacin
Table 86: Finafloxacin - Phase II Efficacy for Patients with UTI
Table 87: Finafloxacin SWOT Analysis, 2017
Table 88: Product Profile - Plazomicin
Table 89: Plazomicin - Clinical Trials
Table 90: Plazomicin - Results from Phase III Trial with cUTI Patients
Table 91: Plazomicin - Results from Phase III Trial with cUTI Patients
Table 92: Plazomicin - Safety Results from Phase III Trials
Table 93: Eravacycline SWOT Analysis, 2017
Table 94: Product Profile - Panobacumab
Table 95: Aerumab - Phase II Clinical Trials
Table 96: Aerumab - Phase II Clinical Trial Results
Table 97: Aerumab SWOT Analysis, 2017
Table 98: Product Profile - MEDI3902
Table 99: MEDI3902 - Phase II Clinical Trials
Table 100: MEDI3902 - Safety Data
Table 101: MEDI3902 SWOT Analysis, 2017
Table 102: Drugs in Development for HAI Caused by Gram-Negative Bacteria, 2017
Table 103: Key Companies in the HAIs Marketplace in the 7MM, 2017
Table 104: Pfizer’s HAI Portfolio Assessment, 2017
Table 105: Merck& Co’s Gram-Negative HAIs Portfolio Assessment, 2017
Table 106: The Medicines Company’s Gram-Negative HAIs Portfolio Assessment, 2017
Table 107: Shionogi’s Gram-Negative HAIs Portfolio Assessment, 2017
Table 108: Tetraphase Pharmaceutical’s Gram-Negative HAIs Portfolio Assessment, 2017
Table 109: MerLion Pharmaceutical’s Gram-Negative HAIs Portfolio Assessment, 2017
Table 110: Achaogen’s Gram-Negative HAIs Portfolio Assessment, 2017
Table 111: Aridis’ HAI Portfolio Assessment, 2017
Table 112: MedImmune’s Gram-Negative HAI Portfolio Assessment, 2017
Table 113: Allergan’s Gram-Negative HAI Portfolio Assessment, 2017
Table 114: Global (7MM) Sales Forecasts ($M) for Therapeutics Against HAIs Caused by Gram-Negative Bacteria, 2016-2026
Table 115: HAIs Caused by Gram-Negative Bacteria - Global Drivers and Barriers, 2016-2026
Table 116: Sales Forecasts ($M) for Therapeutics Against HAIs Caused by Gram-Negative Bacteria in the US, 2016-2026
Table 117: Key Events Impacting Sales for HAIs Caused by Gram-Negative Bacteria in the US, 2016-2026
Table 118: HAIs caused by Gram-Negative Bacteria - US Drivers and Barriers, 2016-2026
Table 119: 5EU Sales Forecasts ($M) for Therapeutics Against HAIs Caused by Gram-Negative Bacteria, 2016-2026
Table 120: Key Events Impacting Sales for HAIs Caused by Gram-Negative Bacteria in the 5EU, 2016-2026
Table 121: HAIs Caused by Gram-Negative Bacteria - 5EU Drivers and Barriers, 2016-2026
Table 122: Sales Forecasts ($M) for Therapeutics Against HAIs Caused by Gram-Negative Bacteria in Japan, 2016-2026
Table 123: Key Events Impacting Sales for HAIs Caused by Gram-Negative Bacteria in Japan, 2016-2026
Table 124: HAIs Caused by Gram-Negative Bacteria - Japan Drivers and Barriers, 2016-2026
Table 125: Key Historical and Projected Launch Dates for HAI Caused by Gram-negative Bacteria Across the 7MM
Table 126: Projected Patent Expiry Dates for HAI Caused by Gram-negative Bacteria Across the 7MM
Table 127: Key Assumptions for Avycaz
Table 128: Key Assumptions for Zerbaxa
Table 129: Key Assumptions for Piperacillin/tazobactam
Table 130: Key Assumptions for Ticarcillin/tazobactam
Table 131: Key Assumptions for Aztreonam
Table 132: Key Assumptions for Doribax
Table 133: Key Assumptions for Invanz
Table 134: Key Assumptions for Meropenem
Table 135: Key Assumptions for Imipenem
Table 136: Key Assumptions for Cefoxitin
Table 137: Key Assumptions for Cefotaxime
Table 138: Key Assumptions for Ceftriaxone
Table 139: Key Assumptions for Cefoperazone
Table 140: Key Assumptions for Ceftazidime
Table 141: Key Assumptions for Cefepime
Table 142: Key Assumptions for Zevtera
Table 143: Key Assumptions for Levofloxacin
Table 144: Key Assumptions for Ciprofloxacin
Table 145: Key Assumptions for Moxifloxacin
Table 146: Key Assumptions for Amikacin
Table 147: Key Assumptions for Gentamicin
Table 148: Key Assumptions for Tobramycin
Table 149: Key Assumptions for Polymyxin B
Table 150: Key Assumptions for Polymyxin E
Table 151: Key Assumptions for Tygacil
Table 152: Key Assumptions for Other Antibiotics
Table 153: High-Prescribing Physicians (Non-KOLs) Surveyed, By Country

List of Figures
Figure 1: Global Sales for HAI Caused by Gram-Negative Bacteria by Region, 2016 and 2026
Figure 2: Company Portfolio Gap Analysis for HAIs against Gram-Negative Bacteria, 2016-2026
Figure 3: Competitive Assessment of the Late-Stage Pipeline for HAIs against Gram-Negative Bacteria
Figure 4: Illustration Depicting the Key Structural Properties of Gram-Negative Bacteria
Figure 5: Sites of Relevant Gram-Negative HAI Sites
Figure 6: Illustration Depicting the Key Mechanisms of Antibiotic Resistance Observed in Gram-Negative Bacteria
Figure 7: Sources Used to Forecast Suspected Incident Cases of HAIs and Suspected Incident Cases of HAIs by Infection Site
Figure 8: Sources Used and Not Used to Forecast Diagnosed Incident Cases of Gram-Negative HAIs and Diagnosed Incident Cases of Gram-Negative HAIs by Infection Site
Figure 9: Sources Used and Not Used to Forecast Diagnosed Incident Cases of Gram-Negative HAIs by Infection Site by Causative Agent
Figure 10: 7MM, Suspected Incident Cases of Select HAIs by Infection Site, Both Sexes, Ages =18 Years, 2016
Figure 11: 7MM, Diagnosed Incident Cases of Select Gram-Negative HAIs by Infection Site, Both Sexes, Ages =18 Years, 2016
Figure 12: 7MM, Diagnosed Incident Cases of Gram-Negative CAUTI by Causative Agent, Both Sexes, Ages =18 Years, 2016
Figure 13: 7MM, Diagnosed Incident Cases of Gram-Negative CLABSI by Causative Agent, Both Sexes, Ages =18 Years, 2016
Figure 14: 7MM, Diagnosed Incident Cases of Gram-Negative HAP/VAP by Causative Agent, Both Sexes, Ages =18 Years, 2016
Figure 15: 7MM, Diagnosed Incident Cases of Gram-Negative SSI by Causative Agent, Both Sexes, Ages =18 Years, 2016
Figure 16: Empirical and Targeted Treatments of HAIs
Figure 17: Overview of the Unmet Needs for HAIs Caused by Gram-Negative Bacteria.
Figure 18: Overview of the Development Pipeline for HAI Against Gram-Negative Bacteria
Figure 19: HAIs Caused by Gram-Negative Bacteria - Phase II?III Pipeline, 2017
Figure 20: Competitive Assessment of Late-Stage Pipeline Agents in HAIs Caused by Gram-Negative Bacteria, 2016-2026
Figure 21: Clinical and Commercial Positioning of Aztreonam/Avibactam
Figure 22: Clinical and Commercial Positioning of Meropenem/Vaborbactam
Figure 23: Clinical and Commercial Positioning of Relebactam/Imipenem/Cilastin
Figure 24: Clinical and Commercial Positioning of Cefiderocol
Figure 25: Clinical and Commercial Positioning of Eravacycline
Figure 26: Clinical and Commercial Positioning of Finafloxacin
Figure 27: Clinical and Commercial Positioning of Plazomicin
Figure 28: Clinical and Commercial Positioning of Aerumab
Figure 29: Clinical and Commercial Positioning of MEDI3902
Figure 30: Company Portfolio Gap Analysis in Gram-Negative HAIs, 2016-2026
Figure 31: Global Sales for Therapeutics Against HAIs Caused by Gram-Negative Bacteria, by Country/Region, 2016 and 2026
Figure 32: Global Sales for Therapeutics Against HAIs Caused by Gram-Negative Bacteria, by Drug Class, 2016 and 2026
Figure 33: Sales for Therapeutics Against HAIs Caused by Gram-Negative Bacteria in the US, by Drug Class, 2016 and 2026
Figure 34: Sales for Therapeutics Against HAIs Caused by Gram-Negative Bacteria in the 5EU by Drug Class, 2016 and 2026
Figure 35: Sales for Therapeutics Against HAIs Caused by Gram-Negative Bacteria in Japan, by Drug Class, 2016 and 2026
Figure 36: Patient Flow Used for HAIs with Gram-Negative Bacteria
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Pfizer
  • Merck& Co.
  • The Medicines Company
  • Shionogi & Co., Ltd.
  • Tetraphase Pharmaceuticals Inc.
  • MerLion Pharmaceuticals Pte., Ltd.
  • Achaogen
  • Aridis Pharmaceuticals
  • MedImmune LLC
  • Allergan
  • Roche/Genentech
  • Wockhardt Ltd.
  • Allecra
  • Zavante
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll